Antitumor Activity of Adriamycin (Hydrazone-linked) Immunoconjugates Compared with Free Adriamycin and Specificity of Tumor Cell Killing

Cancer Research

Volumn 50, Issue 20, 1990, Pages 6608-6614

  Braslawsky, Gary R ^a   Edson, Mary A ^a   Pearce, Walter ^a   Kaneko, Takushi ^a   Greenfield, Robert S ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

ANIMAL EXPERIMENT; ANTIBODY LABELING; ARTICLE; BURKITT LYMPHOMA; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION; TUMOR XENOGRAFT;

ANIMAL; ANTIBODIES, MONOCLONAL; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMAN; HYDRAZONES; IMMUNOTOXINS; LYMPHOMA; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; TRANSPLANTATION, HETEROLOGOUS;

EID: 0025027766     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Weinstein, H. J., Mayer, R. J., and Rosenthal, D. S. Treatment of acute myelogenous leukemia in children and adults. N. Engl. J. Med., 303: 473–478, 1980.
2. McCredie, K. B., Bodey, G. P., Freireich, E. J., Hester, J. P., Rodriguez, V., and Keating, M. J. Chemoimmunotherapy of adult acute leukemia. Cancer (Phila.), 47(6): 1256–1261, 1981.
3. Smalley, R. V., and Bartolucci, A. A. Variations in responsiveness and survival of clinical subsets of patients with metastatic breast cancer to two chemotherapy combinations. Eur. J. Cancer, (Suppl. 1): 141–146, 1980.
4. Bruckner, H. W., Cohen, C. J., Goldenberg, J. D., Kabakon, B., Wallach, R. C., Deppe, G., Greenspan, E. M., Grusberg, S. B., and Holland, J. F. Improved chemotherapy for ovarian carcinoma with cis-diaminedichloroplat-inum and Adriamycin. Cancer (Phila.), 47(9): 2288–2294, 1981.
5. Carter, S. K. Adriamycin. A review. J. Natl. Cancer Inst., 55: 1265–1274, 1975.
6. Blair, A. H., and Ghose, T. I. Linkage of cytotoxic agents to immunoglobulins. J. Immunol. Methods, 59: 129–143, 1983.
7. Ohkawa, K., Tsukada, Y., Hibi, N., Umemoto, N., and Hara, T. Selective in vitro and in vivo growth inhibition against human yolk sac tumor cell lines by purified antibody against human α-fetoprotein conjugated with mitomycin C via human serum albumin. Cancer Immunol. Immunother., 23: 81–86, 1986.
8. Rowland, G. F., Axton, C. A., Baldwin, R. W., Brown, J. P., Corvalan, J. R. F., Embleton, M. J., Gore, U. A., Hellstrom, I., Hellstrom, K. E., Jacobs, E., Marsden, C. H., Pimm, M. V., Simmonds, R. G., and Smith, W. Antitumor properties of vindesine-monoclonal antibody conjugates. Cancer Immunol. Immunother., 19: 1–7, 1985.
9. Freeman, A. I., and Mayhew, E. Targeted drug delivery. Cancer (Phila.), 58: 573–583, 1986.
10. Ghose, T. I., Blair, A. H., and Kulkarni, P. N. Preparation of antibody-linked cytotoxic agents. Methods Enzymol., 93: 280–333, 1983.
11. Arnon, R., and Sela, M. In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumor antibodies. Immunol. Rev., 62: 5–27, 1982.
12. Levy, R., Hurwitz, E., Maron, R., Arnon, R., and Sela, M. The specific cytotoxic effects of daunomycin conjugated to anti-tumor antibodies. Cancer Res., 35: 1182–1186, 1975.
13. Yang, H. M., and Reisfeld, R. A. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc. Natl. Acad. Sci. USA, 85: 1189–1193, 1988.
14. Dillman, R. O., Johnson, D. E., Shawler, D. L., and Koziol, J. A. Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug. Cancer Res., 48: 6097–6102, 1988.
15. Gallego, J., Price, M. R., and Baldwin, R. W. Preparation of four dauno-mycin-monoclonal antibody 791T/36 conjugates with anti-tumor activity. Int. J. Cancer, 33: 737–744, 1984.
16. Pieterz, G. A., Smyth, M. J., and McKenzie, I. F. Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates. Cancer Res., 48: 926–931, 1988.
17. Lenaz, L. and Marco, D. M. On the reported lack of effectiveness of daunomycin (NSC-82.151) and Adriamycin (NSC-123127) on solid tumor. Cancer Chemother. Rep., 56 (4, part 1): 431–432, 1972.
18. Greenfield, R. S., Kaneko, T., Daues, A., Edson, M. A., Fitzgerald, K. A., Olech, L. J., Grattan, J. A., and Braslawsky, G. R. Evaluation in vitro of Adriamycin immunoconjugates synthesized using an acid-sensitive hydra-zone linker. Cancer Res., 50: 6600–6607, 1990.
19. Bruck, C., Portetelli, D., Glineur, C., and Bollen, H. One step purification of mouse monoclonal antibodies from ascitic fluid by DEAE-affigel blue chromatography. J. Immunol. Methods, 53: 313–319, 1982.
20. Greenfield, R. S., Braslawsky, G. R., Olech, L., and Kaneko, T. Anthracycline immunoconjugates having a novel linker and methods for their production. European Patent Appl. Pub. No. 0 328 147, 1989.
21. Begg, A. C. Principles and practices of the tumor growth delay assay. In: R. F. Kallman (ed.), Rodent Tumor Models in Experimental Cancer Therapy. New York: Pergamon Press, 1987.
22. Winer, B. J. Statistical Principles in Experimental Designs, pp. 514–539. New York: McGraw-Hill Bank Co., 1971.
23. Dillman, R. O., Shawler, D. L., Johnson, D. E., Meyer, D. L., Koziol, J. A., and Frincke, J. E. Comparative preclinical trials with combinations and conjugates of T101 and doxorubicin. Cancer Res., 46: 4886–4891, 1986.
24. Pastan, I., and Willingham, M. C. (eds.). Pathway of endocytosis. In: Endocytosis, pp. 1–44. New York: Plenum Publishing Corp., 1985.
25. Smyth, M. J., Pietersz, G. A., and McKenzie, I. F. The mode of action of methotrexate-monoclonal antibody conjugates. Immunol. Cell Biol., 65: 189–200, 1987.
26. Uadia, P., Blair, A. H., Ghose, T., and Ferrone, S. Uptake of methotrexate linked to polyclonal and monoclonal antimelanoma antibodies by a human cell line. J. Natl. Cancer Inst., 74: 29–35, 1985.
27. Maske, J. M., Buchsbaum, D. J., Azemove, S. M., Hanna, D. E., and Vallera, D. A. Antigenic modulation by anti-CD5 immunotoxins. J. Immunol., 136: 4721–4728, 1986.